About

About Invitris GmbH Invitris co-develops highly complex multi-proteins using a scalable in vitro protein synthesis platform. Invitris provides both drug discovery & development, and can also provide GMP manufacturing without extensive process development. Invitris product portfolio includes synthetic bacteriophages, endolysins, tailocins, neoantigens, antibodies, ADCs, proteases, nucleases, enzymes, and many more. About Invitris GmbH Invitris co-develops highly complex multi-proteins using a scalable in vitro protein synthesis platform. Invitris provides both drug discovery & development, and can also provide GMP manufacturing without extensive process development. Invitris product portfolio includes synthetic bacteriophages, endolysins, tailocins, neoantigens, antibodies, ADCs, proteases, nucleases, enzymes, and many more. We own a cell-free in vitro expression technology platform, PhactoryTM, to help co-develop & manufacture the next generation of proteins. We are capable of both prokaryotic and Mammalian cell-free expression. Our focus areas are microbial and Mammalian proteins, including bacteriophages, viruses, endolysins, tailocins, enzymes, antibodies, nanobodies, and more. We're active in the fields of oncology, neurogenerative diseases, antibiotics, agriculture, technical industries, and more. x